The latest price target for Hillstream BioPharma (NASDAQ: HILS) was reported by Dawson James on July 17, 2023. The analyst firm set a price target for $0.00 expecting HILS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Hillstream BioPharma (NASDAQ: HILS) was provided by Dawson James, and Hillstream BioPharma downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hillstream BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hillstream BioPharma was filed on July 17, 2023 so you should expect the next rating to be made available sometime around July 17, 2024.

While ratings are subjective and will change, the latest Hillstream BioPharma (HILS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Hillstream BioPharma (HILS) is trading at is $0.23, which is out of the analyst’s predicted range.

The latest price target for Hillstream BioPharma (NASDAQ: HILS) was reported by Dawson James on July 17, 2023. The analyst firm set a price target for $0.00 expecting HILS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Hillstream BioPharma (NASDAQ: HILS) was provided by Dawson James, and Hillstream BioPharma downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hillstream BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hillstream BioPharma was filed on July 17, 2023 so you should expect the next rating to be made available sometime around July 17, 2024.

While ratings are subjective and will change, the latest Hillstream BioPharma (HILS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Hillstream BioPharma (HILS) is trading at is $0.23, which is out of the analyst’s predicted range.

The latest price target for Hillstream BioPharma (NASDAQ: HILS) was reported by Dawson James on July 17, 2023. The analyst firm set a price target for $0.00 expecting HILS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Hillstream BioPharma (NASDAQ: HILS) was provided by Dawson James, and Hillstream BioPharma downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hillstream BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hillstream BioPharma was filed on July 17, 2023 so you should expect the next rating to be made available sometime around July 17, 2024.

While ratings are subjective and will change, the latest Hillstream BioPharma (HILS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Hillstream BioPharma (HILS) is trading at is $0.23, which is out of the analyst’s predicted range.

The latest price target for Hillstream BioPharma (NASDAQ: HILS) was reported by Dawson James on July 17, 2023. The analyst firm set a price target for $0.00 expecting HILS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Hillstream BioPharma (NASDAQ: HILS) was provided by Dawson James, and Hillstream BioPharma downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hillstream BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hillstream BioPharma was filed on July 17, 2023 so you should expect the next rating to be made available sometime around July 17, 2024.

While ratings are subjective and will change, the latest Hillstream BioPharma (HILS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Hillstream BioPharma (HILS) is trading at is $0.23, which is out of the analyst’s predicted range.

The latest price target for Hillstream BioPharma (NASDAQ: HILS) was reported by Dawson James on July 17, 2023. The analyst firm set a price target for $0.00 expecting HILS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Hillstream BioPharma (NASDAQ: HILS) was provided by Dawson James, and Hillstream BioPharma downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hillstream BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hillstream BioPharma was filed on July 17, 2023 so you should expect the next rating to be made available sometime around July 17, 2024.

While ratings are subjective and will change, the latest Hillstream BioPharma (HILS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Hillstream BioPharma (HILS) is trading at is $0.23, which is out of the analyst’s predicted range.

The latest price target for Hillstream BioPharma (NASDAQ: HILS) was reported by Dawson James on July 17, 2023. The analyst firm set a price target for $0.00 expecting HILS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Hillstream BioPharma (NASDAQ: HILS) was provided by Dawson James, and Hillstream BioPharma downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hillstream BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hillstream BioPharma was filed on July 17, 2023 so you should expect the next rating to be made available sometime around July 17, 2024.

While ratings are subjective and will change, the latest Hillstream BioPharma (HILS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Hillstream BioPharma (HILS) is trading at is $0.23, which is out of the analyst’s predicted range.

The latest price target for Hillstream BioPharma (NASDAQ: HILS) was reported by Dawson James on July 17, 2023. The analyst firm set a price target for $0.00 expecting HILS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Hillstream BioPharma (NASDAQ: HILS) was provided by Dawson James, and Hillstream BioPharma downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hillstream BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hillstream BioPharma was filed on July 17, 2023 so you should expect the next rating to be made available sometime around July 17, 2024.

While ratings are subjective and will change, the latest Hillstream BioPharma (HILS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Hillstream BioPharma (HILS) is trading at is $0.23, which is out of the analyst’s predicted range.

The latest price target for Hillstream BioPharma (NASDAQ: HILS) was reported by Dawson James on July 17, 2023. The analyst firm set a price target for $0.00 expecting HILS to fall to within 12 months (a possible -100.00% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Hillstream BioPharma (NASDAQ: HILS) was provided by Dawson James, and Hillstream BioPharma downgraded their neutral rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hillstream BioPharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hillstream BioPharma was filed on July 17, 2023 so you should expect the next rating to be made available sometime around July 17, 2024.

While ratings are subjective and will change, the latest Hillstream BioPharma (HILS) rating was a downgraded with a price target of $0.00 to $0.00. The current price Hillstream BioPharma (HILS) is trading at is $0.23, which is out of the analyst’s predicted range.